Ipilimumab-Induced Neutropenia in Melanoma. (August 2016)

• Record Type: Journal Article
• Authors: Ban-Hoefen, Makiko; Burack, Richard; Sievert, Lynn; Sahasrabudhe, Deepak
• Is Part Of: Journal of investigative medicine high impact case reports. Volume 4:Number 3(2016)
• Publication Date: 2016-08
• Subjects: checkpoint inhibitors -- ipilimumab -- immune-mediated -- neutropenia -- melanoma; Internal medicine -- Periodicals; Medical care -- Periodicals; 616.005
• DOI: 10.1177/2324709616661835
• Languages: English
• ISSNs: 2324-7096

Abstract

Ipilimumab is a human monoclonal IgG1 antibody against CTLA-4 that has been shown to prolong the overall survival of advanced melanoma. The most common adverse events associated with ipilimumab are immune-related. Severe hematological toxicity is rare. We report a case of severe neutropenia following ipilimumab therapy that fully resolved after the administration of prednisone, cyclosporine, and anti-thymocyte globulin therapies.